Galderma Group AG
Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of CD 2027 Spray in Adults With Plaque-type Psoriasis
- First Posted Date
- 2008-10-01
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 26
- Registration Number
- NCT00763503
- Locations
- 🇺🇸
Burke Pharmaceutical Research, Hot Springs, Arizona, United States
🇺🇸DermResearch, Austin, Texas, United States
🇺🇸J & S Studies, Bryan, Texas, United States
Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis
- First Posted Date
- 2008-10-01
- Last Posted Date
- 2022-08-23
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 88
- Registration Number
- NCT00763555
- Locations
- 🇺🇸
Minnesota Clinical Study Center, Fridley, Minnesota, United States
🇺🇸Tennessee Clinical Research Center, Nashville, Tennessee, United States
🇨🇦Stratica Medical, Edmonton, Alberta, Canada
Efficacy/Safety/Subject Satisfaction/Duration of Response of Clobetasol Propionate Spray vs Ointment in Plaque Psoriasis
- Conditions
- Plaque Psoriasis
- Interventions
- First Posted Date
- 2008-08-13
- Last Posted Date
- 2022-08-23
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 250
- Registration Number
- NCT00733954
- Locations
- 🇺🇸
East Bay Dermatology Medical Group, Inc., Fremont, California, United States
🇺🇸Solano Clinical Research, Vallejo, California, United States
🇺🇸Henry Ford Medical Center, Detroit, Michigan, United States
Evaluate Efficacy, Safety & Subject Satisfaction of Pain Management With Pliaglis® Cream for Dermal Filler Injections
- Conditions
- Nasolabial Folds
- Interventions
- First Posted Date
- 2008-07-16
- Last Posted Date
- 2022-08-23
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 51
- Registration Number
- NCT00716443
- Locations
- 🇺🇸
Skin and Cancer Associates, Center for Cosmetic Enhancement, Aventura, Florida, United States
🇺🇸Palm Beach Esthetic Dermatology and Laser Center, West Palm Beach, Florida, United States
🇺🇸Sadick Dermatology, New York, New York, United States
Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%
- Conditions
- Erythematous Rosacea
- Interventions
- Drug: 0.18% COL-118 facial gel (1.8 mg brimonidine)Drug: Advanced Eye Relief
- First Posted Date
- 2008-06-16
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 20
- Registration Number
- NCT00697541
- Locations
- 🇺🇸
KGL, Inc., Broomall, Pennsylvania, United States
Adapalene-Benzoy Peroxide (BPO) Gel in the Treatment of Acne Vulgaris as a 6-month Maintenance
- Conditions
- Acne
- Interventions
- Drug: Vehicle Gel
- First Posted Date
- 2008-06-02
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 243
- Registration Number
- NCT00687908
- Locations
- 🇵🇷
Galderma Investigational Site, Carolina, Puerto Rico
Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris
- Conditions
- Severe Acne Vulgaris
- Interventions
- Drug: Vehicle Gel associated with Doxycycline Hyclate
- First Posted Date
- 2008-06-02
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 459
- Registration Number
- NCT00688064
- Locations
- 🇵🇷
Galderma Investigational Site, Carolina, Puerto Rico
Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris
- Conditions
- Acne Vulgaris
- Interventions
- Drug: clindamycin/benzoyl peroxide gel
- First Posted Date
- 2008-05-05
- Last Posted Date
- 2022-08-23
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 100
- Registration Number
- NCT00671749
- Locations
- 🇺🇸
Center for Dermatology and Laser Surgery, Sacramento, California, United States
🇺🇸Derm Research, P.L.L.C., Louisville, Kentucky, United States
🇺🇸Brodell Medical, Warren, Ohio, United States
An Evaluation of the Cosmetic Appearance of Metronidazole Gel (MetroGel®) 1%
- First Posted Date
- 2008-04-29
- Last Posted Date
- 2022-07-29
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 30
- Registration Number
- NCT00668655
- Locations
- 🇺🇸
Dermatology Consulting Services, High Point, North Carolina, United States
Treatment w/ Tri-Luma® Cream & Intense Pulsed Light (IPL) vs a Mild Inactive Control Cream & Intense Pulsed Light (IPL) in Melasma
- Conditions
- Melasma
- Interventions
- Drug: Cetaphil® Moisturizing Cream as Inactive Control
- First Posted Date
- 2008-04-29
- Last Posted Date
- 2022-08-23
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 56
- Registration Number
- NCT00669071
- Locations
- 🇺🇸
Dermatology/Cosmetic Laser Associates of La Jolla, Inc., La Jolla, California, United States
🇺🇸Tennessee Clinical Research Center, Nashville, Tennessee, United States